Blood Coagulation Reagent Kit for FVIII-Substituting Activity Evaluation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods struggle to accurately evaluate the efficacy of substances with FVIII-substituting activity, such as bispecific antibodies, used in treating hemophilia, due to differences in blood coagulation mechanisms compared to traditional FVIII-based therapies.

Innovation Solution

A method involving a reagent kit that includes a coagulation factor XII-activating agent, phospholipids, tissue factor, and a calcium ion-containing aqueous solution, which is used to prepare a measurement sample from a blood specimen obtained from a subject administered a substance with FVIII-substituting activity. This sample is then irradiated with light to acquire optical information, allowing for the evaluation of coagulability based on specific parameters.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If existing APTT measurement methods are used to evaluate substances with FVIII-substituting activity, then the measurement can be performed with standard equipment, but the measurement precision and sensitivity are insufficient to accurately reflect actual efficacy

Engineering Contradiction:

Improveefficacy evaluation accuracyVSAvoidmeasuring equipment requirement

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent modifies the APTT measurement parameters by changing the reagent composition (adding phospholipids and tissue factor at specific concentrations) and measurement conditions (incubation temperature and time) to enhance sensitivity for detecting FVIII-substituting activity while maintaining compatibility with standard coagulation analyzers

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a modified version of the standard APTT test that replicates the enhanced sensitivity of specialized thrombin generation assays by optimizing reagent parameters, allowing standard equipment to achieve improved measurement precision through reagent formulation rather than requiring new instrumentation

Inventive Principle:

Principle #26Copying

2Measurement precision

If specialized thrombin generation measurement equipment is used to evaluate substances with FVIII-substituting activity, then the measurement precision and sensitivity are improved, but the device complexity and cost increase

Engineering Contradiction:

Improveefficacy evaluation accuracyVSAvoidmeasuring equipment requirement

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent introduces optimized reagents (containing specific concentrations of phospholipids, tissue factor, and calcium ions) as an intermediary that bridges the gap between standard APTT equipment and specialized thrombin generation assays, enabling enhanced measurement capability through chemical mediation rather than requiring complex instrumental modifications

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the need for complex specialized measurement equipment with a simplified reagent-based solution that uses standard coagulation analyzers, substituting mechanical/instrumental complexity with optimized chemical parameters and measurement protocols

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Ease of operation

If standard APTT reagents are used for coagulation waveform analysis, then the ease of operation is maintained, but the sensitivity to detect FVIII-substituting activity is insufficient

Engineering Contradiction:

Improveoperational simplicityVSAvoidsensitivity to FVIII-substituting activity

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent optimizes multiple reagent parameters simultaneously (phospholipid concentration, tissue factor concentration, calcium ion concentration, incubation temperature, and incubation time) to achieve enhanced sensitivity while maintaining the same operational workflow and equipment, demonstrating that parameter optimization can improve performance without complicating operation

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The proposed method enables appropriate evaluation of coagulability in blood specimens containing substances with FVIII-substituting activity, providing a sensitive and effective means to assess the efficacy of such substances.

Implementation Method 1

irradiating the measurement sample with light to acquire optical information on the light amount from the measurement sample

Methodology Applied

Scientific EffectLight absorption: Absorption (EM radiation)

Data Source

PatentEP3287791B1Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to be used therein

Publication Date: 2025.02.19 CHUGAI PHARMA CO LTD

Figure 1~2
Figure 3A~3B
Figure 4

AI summary

The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention relates to an apparatus and computer program for evaluating coagulability of a blood specimen.